admin

Engineered Medical Systems, Longeviti Neuro Solutions and The LaunchPort™ announced today that they have entered into an agreement to place new, low temperature, low toxicity hydrogen peroxide sterilization capacity at The LaunchPort™/EMS facility in Port Covington. The systems are being procured by Longeviti to support the Maryland production of their Low-profile Intracranial Devices (L.I.D.) platform. The Longeviti L.I.D. Platform has led to several innovative FDA cleared products thus far, the ClearFit and InvisiShunt, and more are in development. The systems will be operated by Engineered Medical Systems within EMS’s regulated medical manufacturing facility at LaunchPort™. These new systems are expected to have completed initial validations by the end of Q1 2020.

Image: https://www.prweb.com

Herndon, VA, Jan. 14, 2020 (GLOBE NEWSWIRE) — The Center for Innovative Technology (CIT) today released the 2019 CIT GAP Funds Impact Report, detailing both return on investment and socio-economic impact made since the fund’s inception in 2005. A family of funds placing equity investments in Virginia’s high-growth based technology, life science, and cleantech companies at the earliest developmental stages, CIT GAP Funds has deployed $28.8 million in capital across 223 investments. CIT GAP Funds investment leadership has attracted national recognition and continues to demonstrate why CIT has been named Virginia’s Most Active Investor for the last five years by CB Insights.CIT GAP Funds has yielded four times their capital invested across Tech Fund “Roadmap” investments in cybersecurity, data analytics, enterprise software and deep tech sectors and helped position the fund for return of all capital deployed. The report highlights several other figures that capture the overall impact CIT GAP Funds has on the Commonwealth, including:

Image: https://www.streetinsider.com

The seller converted the office space — leased heavily by local biotech companies — to lab suites, then sold the buildings just three years after buying them.

Image: The buildings at West Watkins Mill Road and Clopper Road collectively sold for $53.25 million. COURTESY TRITOWER FINANCIAL

The BioHealth Capital Region (BHCR) experienced significant change in 2019 that has set the table for an intriguing 2020.

How 2020 plays out across the region is unknown.

However, if you’ve followed BioBuzz throughout the past year, it is abundantly clear that workforce development strategy, investment, and support will be a critical issue for the next decade in the BHCR. In addition to change and growth across more traditional life science sectors, the ascension of personalized medicine within the region, which includes a host of new and growing regenerative medicine, cell therapy, and gene therapy companies, has transformed the region’s workforce needs.

A Baltimore business incubator has been named among the best in the world.

Emerging Technology Centers in Baltimore has been recognized by UBI Global as one of the 10 best public business incubators in the world.

The ranking was created based on a world benchmark study that included a total of 1,580 programs worldwide assessed on 21 key performance indicators including economy enhancement, talent retention, access to funds, post-graduation performance of companies and more to create lists of the top university, public and private incubators.

Image: The ETC is located at the King Cork & Seal building in Highlandtown. CONTROL TEC INC, & METRO DEVELOPMENT LLC

LOS ANGELES, Jan. 15, 2020 /PRNewswire/ — USA News Group – A new study published in the journal Molecular Therapy reports that researchers found a drug used in the treatment of HIV that may also suppress Zika virus infection. Zika virus disease is caused by a virus transmitted primarily by Aedes mosquitoes, which bite during the day.

Research and developments with multidisciplinary approaches are proving vital to the treatment and defense against viral and infection diseases as they become more aggressive and deadly. Companies preparing to offer new treatments to deal with the onslaught may become some of valuable over the next decade. Leaders in this space are anticipating strong revenue from collaborations including NGM Biopharmaceuticals Inc. (NASDAQ: NGM), Emergent BioSolutions Inc. (NYSE: EBS), and SIGA Technologies, Inc. (NASDAQ: SIGA)

SAN FRANCISCO—Roche has inked a 15-year partnership with Illumina in oncology, which will include collaborating on new companion diagnostic indications for the DNA sequencing giant’s pan-cancer assay.

Announced during the J.P. Morgan Healthcare Conference, the nonexclusive pact will also enable Roche to develop and distribute in vitro diagnostic tests for Illumina’s current and future hardware lines—such as the NextSeq 550Dx and the upcoming NovaSeqDx system. The deal’s financial terms were not disclosed. 

Image: Roche and Illumina, as well as Roche’s Foundation Medicine division, will work to secure regulatory approvals for Illumina’s TruSight Oncology 500 assay as a pan-cancer companion diagnostic for different targeted therapies. (Illumina)

GERMANTOWN, Md., Jan. 6, 2020 /PRNewswire/ — Precigen, Inc., a biopharmaceutical company specializing in the development of innovative gene and cellular therapies to improve the lives of patients, today announced that the US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to PRGN-3006, a first-in-class investigational therapy using Precigen’s non-viral UltraCAR-T™ therapeutic platform for patients with relapsed or refractory acute myeloid leukemia (AML) (clinical trial identifier: NCT03927261). Precigen announced in Q3 2019 that it had completed enrollment for the first cohort of this clinical trial and expects an initial data readout in the second half of 2020.

The National Institute of Standards and Technology is seeking public feedback on its plan to revamp the Interagency Edison (iEdison) System, an online portal where companies that receive federal government funding report their inventions.

The project is part of NIST’s increased focus on federal technology transfer as part of the Lab-to-Market Cross-Agency Priority Goal under the President’s Management Agenda. Every year the federal government invests more than $100 billion in research and development, and in return grantees report the inventions that come out of this funding to the government through iEdison.